Increased reporting of fatal pneumonitis associated with immune checkpoint inhibitors – a WHO pharmacovigilance database analysis
- Melissa Y.Y. Moey1,
- Paul Gougis2,
- Vincent Goldschmidt2,
- Douglas B. Johnson3,
- Bénédicte Lebrun-Vignes2,3,
- Javid Moslehi4,
- Jacques Cadranel5⇑ and
- Joe-Elie Salem2,4
- 1Department of Cardiovascular Sciences, Vidant Medical Center/East Carolina University, Greenville, NC, USA
- 2Department of Pharmacology, INSERM CIC-1901, UNICO-GRECO Cardio-oncology Program, CLIP2 Galilée, APHP.Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France
- 3Pitié and Saint Antoine Pharmacovigilance Centres, APHP. Sorbonne Université, Paris, France and UPEC EA EpiDermE 7379
- 4Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
- 5Chest Department, Thoracic Oncology Expert Center, Rare Pulmonary Diseases Constitutive Center, GRC #4, Theranoscan Sorbonne Université and APHP. Sorbonne Université, Hôpital Tenon, Paris, France
- Prof. Jacques Cadranel, Service de Pneumologie, Hôpital Tenon, 4 rue de la Chine 75970, Paris, France. E-mail: jacques.cadranel{at}aphp.fr
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Moey has nothing to disclose.
Conflict of interest: I declare no conflict of interest
Conflict of interest: Dr. Goldschmidt has nothing to disclose.
Conflict of interest: Dr. Johnson reports grants and other from BMS, other from Array Biopharma, other from Jansen, other from Novartis, other from Merck, grants from Incyte, outside the submitted work.
Conflict of interest: Dr. Lebrun-Vignes has nothing to disclose.
Conflict of interest: Dr. Moslehi reports personal fees from BMS, personal fees from Pfizer, personal fees from Audentes, personal fees from Nektar, during the conduct of the study; In addition, Dr. Moslehi has a patent Method for treating checkpoint inhibitors induced adverse events pending.
Conflict of interest: Dr. Cadranel reports grants and personal fees from AZ, personal fees from Roche, personal fees from BMS, personal fees from MSD, outside the submitted work.
Conflict of interest: Dr. SALEM reports personal fees from BMS, outside the submitted work; In addition, Dr. SALEM has a patent Method for treating checkpoint inhibitors induced adverse events pending.
This is a PDF-only article. Please click on the PDF link above to read it.
- Received January 11, 2020.
- Accepted February 9, 2020.
- Copyright ©ERS 2020